News

New research shows bezuclastinib produced high response rates and substantial reductions in disease burden in people with advanced SM.

Hereditary alpha-tryptasemia may help explain persistent mast cell-related symptoms in patients who do not meet criteria for SM.

Anaphylaxis during pregnancy is rare, but women with mast cell disorders such as systemic mastocytosis are at higher risk.

Subtle skin changes — especially widespread red-brown spots — can be an early warning sign of systemic mastocytosis.

A literature review explores the current understanding of SM and other forms of mastocytosis, as well as the existing treatment landscape.

A nine-year research review suggests routine IV cannulation may be unnecessary for most patients undergoing VIT.

Treatment for systemic mastocytosis is shifting toward targeted therapies that address the disease’s biology, expanding options for patients.

Studies suggest that mental health symptoms in SM may be directly caused by overactive mast cells and the chemicals they release.

A recent case report demonstrates that even without detectable KIT mutations, ISM can progress to SSM but may be treatable with imatinib.

A new study found that silica nanoparticles reduce mast cell activation, while titanium dioxide worsens it.